Publications and abstracts
MVP staff and partners have been involved in the publication of scientific papers, and they regularly attend national and international conferences that address issues related to meningitis, epidemiology, and vaccine development. Some of the publications, posters, and/or abstracts not listed in our Research and Development section are listed below.
The PATH Vaccine Resource library provides additional information on meningococcal meningitis, meningococcal vaccines, epidemiology, and vaccine research.
Akweongo P, Dalaba M, Hayden MH, et al. The economic burden of meningitis to households in Kassena-Nankana district of northern Ghana. PLoS One. 2013;8(11):e79880.
Basta NE, Stuart JM, Nascimento MC, et al. Methods for identifying Neisseria meningitidis carriers. A multi-center study in the African meningitis belt. PLoS One. 2013;8(10):e78336.
Beresniak A, Bertherat E, Perea W, et al. A Bayesian network approach to the study of historical epidemiological databases: modelling meningitis outbreaks in the Niger. Bulletin of the World Health Organization. 2012;1(90):412–417.
Brooke S, Harner-Jay CM, Lasher H, Jacoby E. How public-private partnerships handle intellectual property: the PATH experience. In Krattiger A, Mahoney RT, Nelsen L, et al, eds. Intellectual Property Management in Health and Agricultural Innovation: A Handbook. Oxford, UK: MIHR; 2007:1755–1763. (pdf 261 kb).
Caugant DA, Kristiansen PA, Wang X, et al. Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One. 2012;7(9):e46019.
Chaibou M, Bako H, Salisou L, et al. Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010. Vaccine. 2012;30(35):5229–5234. View abstract.
Colombini A, Badolo O, Gessner B, Jaillard P, Seini E, Da Silva A. Costs and impact of meningitis epidemics for the public health system in Burkina Faso. Vaccine. 2011;29(33):5474–5480. View abstract.
Colombini A, Bationo F, Zongo S, et al. Costs for households and community perception of meningitis epidemics in Burkina Faso. Clinical Infectious Diseases. 2009;49(10):1520–1525. View abstract.
Daugla D, Gami J, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. The Lancet. 2013. Available at: http://www.sciencedirect.com/science/article/pii/S0140673613616128.
Djingarey M, Barry R, Bonkoungou M, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience. Vaccine. 2012 Suppl 2:B40–45. View abstract.
Djingarey M, Kandolo D, Lingani C, et al. Evaluation of meningitis surveillance before introduction of serogroup A meningococcal conjugate vaccine — Burkina Faso and Mali. Morbidity and Mortality Weekly Report. 2012;61(50):1025–1028.
Findlow H, Plikaytis B, Aase A, et al. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults. Clinical and Vaccine Immunology. 2009;16(7):969–977. View abstract.
Findlow H, Sow S, Borrow R, et al. Meningococcal group C and w135 immunological hyporesponsiveness in African toddlers. Clinical and Vaccine Immunology. 2011;18(9):1492–1496. View abstract.
Foschiatti M, Hearshaw M, Cescutti P, Ravenscroft N, Rizzo R. Conformational studies of the capsular polysaccharide produced by Neisseria meningitidis group A. Carbohydrate Research. 2009;344(7):940–943. View abstract.
Frasch C, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac (TM). Human vaccines & immunotherapeutics. 2012;8(6):715–724. View abstract.
Greenwood B. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine. 2013;31(11):1453–1457. View abstract.
Harrison LH, Pelton SI, Wilder-Smith A, et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine. 2011;29(18):3363–3371. View abstract.
Hayden MH, Dalaba M, Awine T, et al. Knowledge, attitudes, and practices related to meningitis in northern Ghana. The American Journal of Tropical Medicine and Hygiene. 2013;89(2):265–270, View abstract.
Hirve S, Bavdekar A, Pandit A, et al. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial. Vaccine. 2012;30(45):6456–6460. View abstract.
Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Population Health Metrics. 2013;11:17.
Jodar L, Feavers I, Salisbury D, Granoff D. Development of vaccines against meningococcal disease. The Lancet. 2002;359(9316):1499–1508. View abstract.
Kieny M-P, LaForce M. The promise of conjugate vaccines for Africa. Vaccine. 2007;3(25) Suppl 1:A108–110. View abstract.
Kim SH, Pezzoli L, Yacouba H, et al. Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010. PLoS One. 2012;7(1):1–6.
Kristiansen PA, Ba KA, Sanou I, et al. Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine. BMC Infectious Diseases. 2013;13(363).
Kristiansen PA, Diomandé F, Ba KA, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clinical Infectious Diseases. 2013;56(3):354–363. View abstract.
Kristiansen PA, Diomandé F, Ouédraogo R, et al. Carriage of Neisseria lactamica in 1- to 29-year-old people in Burkina Faso: epidemiology and molecular characterization. Journal of Clinical Microbiology. 2012;50(12):4020–4027. View abstract.
Kristiansen PA, Ouédraogo AS, Sanou I, et al. Laboratory quality control in a multicentre meningococcal carriage study in Burkina Faso. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2012;106(5);289–297. View abstract.
Kshirsagar N, Mur N, Thatte U, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine. 2007; 3(25) Suppl 1:A101–107. View abstract.
LaForce FM, Konde K, Viviani S, Préziosi M-P. The Meningitis Vaccine Project. Vaccine. 2007;3(25) Suppl 1:A97–100. View abstract.
LaForce FM, Okwo-Bele JM. Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Affairs. 2011;30(6):1049–1057. View abstract.
LaForce FM, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solution. Vaccine. 2009;24(27) Suppl 2:B13–19. View abstract.
Lee C, Kuo W, Beri S, et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine. 2009; 27(5):726–732. View abstract.
Lydon P, Zipursky S, Tevi-Benissan C, et al. Economic benefits of keeping vaccines at ambient temperature during mass vaccination: the case of meningitis A vaccine in Chad. Bulletin of the World Health Organization. 2014;1(92):86–92.
Maiden, M. The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis? Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 2013;368:20120147. View abstract.
Marchetti E, Mazarin-Diop V, Chaumont J, et al. Conducting vaccine clinical trials in sub-Saharan Africa: operational challenges and lessons learned from the Meningitis Vaccine Project. Vaccine. 2012;30(48):6859–6863. View abstract.
Médah I, Yélbeogo D, Kambou JL, et al. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign — Burkina Faso, 2011. Morbidity and Mortality Weekly Report. 2012;61(50):1022–1024.
MenAfriCar Consortium. Meningococcal carriage in the African meningitis belt. Tropical Medicine and International Health. 2013;18(8):968–978. View abstract.
Njanpop-Lafourcade BM, Hugonnet S, Djogbe H, et al. Mobile microbiological laboratory support for evaluation of a meningitis epidemic in northern Benin. PLoS One. 2013;8(7):e68401.
Novak R, Kambou JL, Diomandé F, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. The Lancet Infectious Diseases. 2012;12(10):757–764.
Ouandaogo C, Yameogo T, Diomandé F, et al. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. Vaccine. 2012;30 Suppl 2:B46–B51. View abstract.
Soriano-Gabarro M, Rosenstein N, LaForce FM. Evaluation of serogroup A meningococcal vaccines in Africa: A demonstration project. Journal of Health, Population, and Nutrition. 2004;22(3):275–285. View abstract.
Sow S, Okoko B, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. New England Journal of Medicine. 2011; 364:2293–2304.
Thomson M, Molesworth A, Djingarey M, Yameogo K, Belanger F, Cuevas L. Potential of environmental models to predict meningitis epidemics in Africa. Tropical Medicine & International Health. 2006;11(6):781–788. View abstract.
Tall H, Hugonnet S, Donnen P, et al. Definition and characterization of localised meningitis epidemics in Burkina Faso: a longitudinal retrospective study. BMC Infectious Diseases. 2012;12(2).
World Health Organization (WHO). Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-year experience. Weekly Epidemiological Record. 2005;37(80):313–320. (pdf 537 kb).
World Health Organization (WHO). Managing meningitis epidemics in Africa. A quick reference guide for health authorities and health-care workers. November 2010. WHO/HSE/GAR/ERI/2010.4. (pdf 337 kb).
World Health Organization (WHO). Recommendations to assure the quality, safety and efficacy of group A meningococcal conjugate vaccines. 2006;BS/06.2041. (pdf 442 kb).
World Health Organization (WHO). Standard operating procedures for enhanced meningitis surveillance in Africa. 2009. (pdf 211 kb).
World Health Organization (WHO). Meningococcal disease in countries of the African meningitis belt, 2012 - emerging needs and future perspectives. Weekly Epidemiological Record. 2013;12(88):129–136. (pdf 1.1 mb).
World Health Organization (WHO). Use of MenAfriVac (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns. Guidance for immunization programme decision-makers and managers. WHO/IVB/13.04. (pdf 1.28 mb).
World Health Organization (WHO). Use of MenAfriVac (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns. Training module for organizing immunization sessions. WHO/IVB/13.05. (pdf 1.92 mb).
World Health Organization (WHO). Use of MenAfriVac (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns. Adaptation guide and facillitators guide. WHO/IVB/13.06. (pdf 1.11 mb).
Zipursky S, Djingarey MH, Lodjoc JC, Olodoc L, Tiendrebeogo S, Ronveaux O. Benefits of using vaccines out of the cold chain: Delivering Meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin. Vaccine. 2014;32:1431–1435.
LaForce M. Introduction of a group A meningococcal conjugate vaccine in sub-Saharan Africa: Cost/savings analysis. MVP unpublished data. 2008. (pdf 623 kb).